Publications

Detailed Information

Association of neuromuscular reversal by sugammadex and neostigmine with 90-day mortality after non-cardiac surgery

DC Field Value Language
dc.contributor.authorOh, Tak Kyu-
dc.contributor.authorRyu, Jung-Hee-
dc.contributor.authorNam, Sunwoo-
dc.contributor.authorOh, Ah-Young-
dc.date.accessioned2020-07-30T07:11:35Z-
dc.date.available2020-07-30T16:14:42Z-
dc.date.issued2020-02-20-
dc.identifier.citationBMC Anesthesiology. 2020 Feb 20;20(1):41ko_KR
dc.identifier.issn1471-2253-
dc.identifier.urihttps://hdl.handle.net/10371/168656-
dc.description.abstractAbstract

Background
Reversing a neuromuscular blockade agent with sugammadex is known to lessen postoperative complications by reducing postoperative residual curarization. However, its effects on 90-day mortality are unknown. Therefore, this study aimed to compare the effects of sugammadex and neostigmine in terms of 90-day mortality after non-cardiac surgery.


Methods
This retrospective cohort study analyzed the medical records of adult patients aged 18 years or older who underwent non-cardiac surgery at a single tertiary care hospital between 2011 and 2016. Propensity score matching and Cox regression analysis were used to investigate the effectiveness of sugammadex and neostigmine in lowering 90-day mortality after non-cardiac surgery.


Results
A total of 65,702 patients were included in the analysis (mean age: 52.3 years, standard deviation: 15.7), and 23,532 of these patients (35.8%) received general surgery. After propensity score matching, 14,179 patients (3906 patients from the sugammadex group and 10,273 patients from the neostigmine group) were included in the final analysis. Cox regression analysis in the propensity score-matched cohort showed that the risk of 90-day mortality was 40% lower in the sugammadex group than in the neostigmine group (hazard ratio: 0.60, 95% confidence interval: 0.37, 0.98; P = 0.042). These results were similar in the multivariable Cox regression analysis of the entire cohort (hazard ratio: 0.62, 95% confidence interval: 0.39, 0.96; P = 0.036).


Conclusions
This retrospective cohort study suggested that reversing rocuronium with sugammadex might be associated with lower 90-day mortality after non-cardiac surgery compared to neostigmine. However, since this study did not evaluate quantitative neuromuscular function in the postoperative period due to its retrospective design, the results should be interpreted carefully. Future prospective studies with quantitative neuromuscular monitoring in the postoperative period should be performed to confirm these results.
ko_KR
dc.language.isoenko_KR
dc.publisherBMCko_KR
dc.subjectMuscle relaxation-
dc.subjectMortality-
dc.subjectNeostigmine-
dc.subjectSugammadex-
dc.titleAssociation of neuromuscular reversal by sugammadex and neostigmine with 90-day mortality after non-cardiac surgeryko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor오탁규-
dc.contributor.AlternativeAuthor류정희-
dc.contributor.AlternativeAuthor남선우-
dc.contributor.AlternativeAuthor오아영-
dc.identifier.doi10.1186/s12871-020-00962-7-
dc.citation.journaltitleBMC Anesthesiologyko_KR
dc.language.rfc3066en-
dc.rights.holderThe Author(s)-
dc.date.updated2020-06-17T12:57:19Z-
dc.citation.number1ko_KR
dc.citation.startpage41ko_KR
dc.citation.volume20ko_KR
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share